AC Immune SA

( )
ACIU After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Pharmaceuticals Major
JNJJohnson & Johnson 0.48%160.690.7%$1221.58m
PFEPfizer Inc. 1.17%37.610.9%$1016.38m
MRKMerck & Co., Inc. 0.35%76.670.7%$965.72m
ABBVAbbVie, Inc. 0.94%106.901.9%$828.02m
BMYBristol-Myers Squibb Co. 1.00%64.451.0%$731.74m
LLYEli Lilly & Co. 1.65%186.011.1%$577.53m
AZNAstraZeneca Plc 1.99%50.831.2%$442.51m
GSKGlaxoSmithKline Plc 4.26%37.670.2%$213.98m
RPRXRoyalty Pharma Plc -1.12%41.650.2%$157.73m
NVSNovartis AG 0.52%87.200.2%$153.46m
VTRSViatris, Inc. 0.53%13.280.0%$128.16m
RGENRepligen Corp. 4.03%213.576.8%$89.09m
CVACCureVac NV 1.40%104.050.0%$87.46m
SNYSanofi 0.90%50.690.2%$60.91m
ATNF180 Life Sciences Corp. -4.02%10.040.0%$60.80m

Company Profile

AC Immune SA engages in the discovery and development of therapeutic and diagnostic products for neurodegenerative diseases. It leverages proprietary technology platforms to discover, design, and develop novel, proprietary medicines for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company was founded by Jean-Marie Lehn, Claude Nicolau, Roscoe Brady, Fred van Leuven, Ruth Greferath, Andrea Pfeifer, and Alexey V. Eleesiv on February 13, 2003 and is headquartered in Lausanne, Switzerland.